ANIK

Anika Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↑ 7/10
  • Momentum↓ 4/10
Anika Therapeutics sales and earnings growth
ANIK Growth
Good
  • Revenue Y/Y↓ -6.36%
  • EPS Y/Y↑ 65.86%
  • FCF Y/Y↑ 105.94%
Anika Therapeutics gross and profit margin trends
ANIK Profitability
Low
  • Gross margin ↑ 83.00%
  • EPS margin↓ -40.80%
  • ROIC↓ -23.60%
Anika Therapeutics net debt vs free cash flow
ANIK Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -11.3

Anika Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Medical Devices stocks ↗